pillbase.ru

Blincyto

Active substance: blinatumomab

blinatumomab

Centralised EU authorisationActive

Marketing holder: Amgen Europe B.V.

Verified 2026-10-09 · EMA

Analogues in other countries
Composition
Analogues by country

Products with the same active substance registered in other countries.

CountryProducts
RU 2
  • Блинцито
    порошок для приготовления концентрата для приготовления раствора для инфузий, 35 мкг, 35 мкг (original in Russian, GRLS)
    ЛП-004035
    Амджен Европа Б.В.
  • Блинцито®
    лиофилизат для приготовления концентрата для приготовления раствора для инфузий, 35 мкг, 35 мкг (original in Russian, GRLS)
    ЛП-№(002210)-(РГ-RU)
    Амджен Европа Б.В.
US 1
  • BLINCYTO
    KIT · blinatumomab
    55513-160
    Amgen, Inc
Import and control

Control by country

  • Russiaprescription only

    Source: GRLS (Russian state register) · record 01a120c3-4778-7f78-8eaa-d213353b7462,01a120c5-bbe8-7700-978c-d65610098e70;count=2 · valid from 2026-10-09 · verified 2026-10-09

  • United Statesprescription only

    Source: openFDA NDC · record 01a1208d-4551-735b-bd90-eb67d8fb072b;count=1 · valid from 2026-10-09 · verified 2026-10-09

More on control status
Registration
Registration number
EMEA/H/C/003731
Registration status
Active
ATC code
L01FX07
Sources
  • product · EMA · EMEA/H/C/003731 · Verified 2026-10-09
  • registration_status · EMA · EMEA/H/C/003731 · Verified 2026-10-09
  • ingredients.0 · EMA · EMEA/H/C/003731 · Verified 2026-10-09